Incannex Healthcare Inc. - Common Stock (NQ:IXHL)

3.100 -0.100 (-3.13%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incannex Healthcare Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 07, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 07, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 06, 2023

Via Benzinga

Incannex Approved For Bioavailability Clinical Trial For Dronabinol-Based Drug For Treatment Of Obstructive Sleep Apnea ↗

July 06, 2023

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/bioequivalence (‘BA/BE’) clinical trial on...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 06, 2023

Via Benzinga

Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues ↗

July 01, 2023

Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up...

Via Talk Markets

Incannex appoints principal investigators for pivotal IHL-42X trial

June 19, 2023

Incannex appoints principal investigators for pivotal IHL-42X trial

Via News Direct

Incannex appoints principal investigators for pivotal IHL-42X trial

June 19, 2023

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has appointed two highly experienced lead principal investigators for its Phase 2/3 clinical trial of IHL-42X,...

Via TheNewswire.com

Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue ↗

June 17, 2023

There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD.

Via Talk Markets

Major Psychedelic Compound-Based Research & Development Stocks: June Update ↗

June 10, 2023

Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index

Via Talk Markets

Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More ↗

June 06, 2023

Major Investor Commits $30 Million To Psychedelics Funding

Via Benzinga

Why A National Cannabis Organization Sacked Half Its Staff, CEO Turnovers And More Exec Changes ↗

June 05, 2023

NCIA Sacks Half Of Its Team To Increase Financial Strength

Via Benzinga

May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances ↗

June 01, 2023

Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May.

Via Talk Markets

Incannex welcomes world-leading psychedelics experts to advisory board

June 01, 2023

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) director Peter Widdows tells Proactive the company has appointed three world-renowned psychedelic therapy and science experts to its Clarion Clinics Group...

Via TheNewswire.com

Incannex welcomes world-leading psychedelics experts to advisory board

June 01, 2023

Incannex welcomes world-leading psychedelics experts to advisory board

Via News Direct

Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More ↗

May 23, 2023

Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application...

Via Benzinga

Psychedelic Therapies Soon Available In Australia Via Incannex Healthcare And Subsidiary ↗

May 16, 2023

Biotech giant Incannex Healthcare Ltd (NASDAQ: IXHL) shared a business presentation of its newly formed psychedelic-assisted therapies subsidiary company, Psychennex Pty Ltd.

Via Benzinga

Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More ↗

May 08, 2023

EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations

Via Benzinga

Incannex Stock Trading Higher On Entering A Lease For First Psychedelic-Assisted Psychotherapy Clinic ↗

May 05, 2023

Incannex Healthcare Ltd (NASDAQ: IXHL) (ASX:IHL) announced that its subsidiary company, Clarion Clinics Group Pty Ltd, has entered a lease for riverfront premises in Abbottsford, Melbourne.

Via Benzinga

Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A

May 03, 2023

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics...

Via TheNewswire.com

Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A

May 03, 2023

Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A

Via News Direct

Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More ↗

May 01, 2023

Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued

Via Benzinga

April Psychedelic Drug Stocks Recap: The Ups And Downs ↗

April 30, 2023

Via Talk Markets

New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market ↗

April 25, 2023

Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual...

Via Benzinga

Largest Psychedelic Stocks -3.4% In March ↗

April 02, 2023

The munKNEE Psychedelic Drug Stocks Index was down 3.4% in March but is still +1.2% YTD. The best news is the continuing high price targets being set by analysts.

Via Talk Markets

Cannabis Category Performances Ranged From +8.6% To -7.0% This Week ↗

March 25, 2023

The 5 categories in the cannabis sector perform quite differently from each other and this week was a prime example.

Via Talk Markets

Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More ↗

March 20, 2023

Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered

Via Benzinga

Incannex Healthcare Prepares To Launch Psychedelics Clinics Via New Subsidiary ↗

March 17, 2023

Australia-based biopharma giant Incannex Healthcare Ltd. (NASDAQ: IXHL) has plans to commercialize its psychedelic-assisted psychotherapy business through a new subsidiary venture under the leadership...

Via Benzinga

Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder ↗

March 15, 2023

Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions.

Via Benzinga

Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 15, 2023

Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the company announced the roll out of ReadyStart cGMP Suites for early-stage cell and gene-therapy companies.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.